Array BioPharma Announces Key Additions To Scientific Leadership

       Array BioPharma Announces Key Additions To Scientific Leadership

Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert
E. Winkler, M.D. as Vice President of Clinical Development

PR Newswire

BOULDER, Colo., May 19, 2014

BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ:
ARRY), a biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat patients afflicted
with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D.,
as Chief Scientific Officer and Robert E. Winkler, M.D., as Vice President of
Clinical Research and Development. Dr. Saccomano will oversee Array's
discovery efforts and chemistry, manufacturing and controls (CMC) activities
as a member of the executive management team, reporting to Array's Chief
Executive Officer, Ron Squarer. Dr. Winkler will be responsible for leading
the company's clinical science and operations activities, including its
late-stage multiple myeloma program, filanesib, reporting to Array's Chief
Medical Officer, Michael Needle, M.D.

Nicholas A. Saccomano, Ph.D., appointed Chief Scientific Officer at Array
BioPharma Inc.

"We are pleased to have Nick and Robert join the Array team," said Mr.
Squarer. "Nick has a proven track record in drug discovery from his tenure at
Pfizer as an executive and ultimately a Senior Vice President in R&D. He will
play a critical role in identifying and developing opportunities to expand our
discovery collaboration business. Robert brings significant experience in
advancing drugs through development, which will be key as we look to initiate
a Phase 3 trial with our lead multiple myeloma program later this year."

"I am impressed with the consistent productivity of Array's discovery team,
inventing approximately 18 drugs that have advanced into clinical development
since the company's inception, as well as its impressive roster of alliance
partners," said Dr. Saccomano. "I look forward to working with this talented
team as we look to broaden our collaborative outreach and build on an already
outstanding track record of drug discovery."

Dr. Saccomano is a seasoned leader and mentor with 30 years of experience in
pharmaceutical and biotechnology research and development, with expertise in
discovery research, clinical development, portfolio strategy, technology and
clinical candidate licensing, and scientific partnering. Dr. Saccomano most
recently served as Chief Technology Officer at SomaLogic, Inc. and as Chief
Scientific Officer at Bend Research Inc. While at Pfizer Inc., Dr. Saccomano
held positions of increasing responsibility, including Senior Vice President
in the R&D organization and Vice President of Discovery Technology. As head
of discovery technology, he managed and developed a diverse set of enabling
technologies used broadly across the drug discovery pipeline. During his
tenure, he also directed medicinal sciences, drug discovery and strategic
alliances. Dr. Saccomano obtained his Ph.D. in chemistry from Columbia
University under the direction of Professor Gilbert Stork.

Dr. Winkler developed expertise in drug development strategy and execution,
clinical pharmacology, as well as planning regulatory strategy and leading
successful negotiations with health authorities, through his 15 years of
diverse global assignments in the biotech and pharmaceutical industries. Dr.
Winkler most recently served as Vice President of Global Clinical Development
and Operations at Aptalis Pharma, which was recently acquired by Forest Labs,
where he led the company's drug development programs. Prior to this, Dr.
Winkler held positions of increasing responsibility at Amicus Therapeutics,
serving as Vice President of Clinical Research and Operations, leading drug
development and regulatory preparations in rare genetic diseases. Dr. Winkler
served as a Senior Global Clinical Leader at Novartis Oncology, securing
regulatory approvals for Afinitor® (everolimus) forNeuroendocrine Tumors
through an Oncology Drug Advisory Committee, a blockbuster product that has
surpassed $1 billion in annual sales, as well as an sNDA for
Sandostatin®another key Novartis Oncology blockbuster. Preceding Novartis,
Dr. Winkler held roles of increasing responsibility at Schering-Plough, where
he focused on expanding lifecycle opportunities for PegIntron®. Dr. Winkler
obtained his Medical and Bachelor of Science degrees from the Hebrew
University Hadassah Medical School in Israel.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery,
development and commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Seven Phase 3 or pivotal studies are already
in progress, or are planned to begin this year. These programs include the
wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and
two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162
/ Novartis). For more information on Array, please go to

Array BioPharma Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
about Array's clinical development plans and the contribution of Dr. Saccomano
and Dr. Winkler to advancing Array's drug development pipeline. These
statements involve significant risks and uncertainties,including those
discussed in our annual report filed on form 10-K for the year ended June 30,
2013 and in other reports filed by Array with the Securities and Exchange
Commission. Because these statements reflect our current expectations
concerning future events, our actual results could differ materially from
those anticipated in these forward-looking statements as a result of many
factors. These factors include, but are not limited to, our ability to
continue to fund and successfully progress internal research efforts and to
create effective, commercially viable drugs, our ability to achieve and
maintain profitability, the extent to which the pharmaceutical and
biotechnology industries are willing to in-license drug candidates for their
product pipelines and to collaborate with and fund third parties on their drug
discovery activities, our ability to out-license our proprietary candidates on
favorable terms, risks associated with our dependence on our collaborators for
the clinical development and commercialization of our out-licensed drug
candidates, the ability of our collaborators and of Array to meet objectives
tied to milestones and royalties, and our ability to attract and retain
experienced scientists and management. We are providing this information as
of May 19, 2014. We undertake no duty to update any forward-looking statements
to reflect the occurrence of events or circumstances after the date of such
statements or of anticipated or unanticipated events that alter any
assumptions underlying such statements.

Array BioPharma.

CONTACT: Tricia Haugeto
         Array BioPharma Inc.
         (303) 386-1193

Photo -


SOURCE Array BioPharma Inc.

Press spacebar to pause and continue. Press esc to stop.